vir-10q_20210331.htm
false Q1 0001706431 --12-31 P90D true 0.05 0.14 0.08 0.05 0.72 0.60 0.14 0.72 0.67 0.002 0.00 0.002 us-gaap:AccruedLiabilitiesAndOtherLiabilities us-gaap:AccruedLiabilitiesAndOtherLiabilities P8Y7M6D P8Y8M12D P8Y8M12D P7Y7M6D P6Y1M6D P6Y1M6D 1.031 0.888 1.061 0.952 0.006 0.007 0.012 0.012 0001706431 2021-01-01 2021-03-31 xbrli:shares 0001706431 2021-05-03 iso4217:USD 0001706431 2021-03-31 0001706431 2020-12-31 iso4217:USD xbrli:shares 0001706431 us-gaap:GrantMember 2021-01-01 2021-03-31 0001706431 us-gaap:GrantMember 2020-01-01 2020-03-31 0001706431 vir:ContractRevenueMember 2021-01-01 2021-03-31 0001706431 vir:ContractRevenueMember 2020-01-01 2020-03-31 0001706431 2020-01-01 2020-03-31 0001706431 us-gaap:CommonStockMember 2020-12-31 0001706431 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001706431 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001706431 us-gaap:RetainedEarningsMember 2020-12-31 0001706431 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001706431 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001706431 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001706431 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001706431 us-gaap:CommonStockMember 2021-03-31 0001706431 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001706431 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001706431 us-gaap:RetainedEarningsMember 2021-03-31 0001706431 us-gaap:CommonStockMember 2019-12-31 0001706431 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001706431 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001706431 us-gaap:RetainedEarningsMember 2019-12-31 0001706431 2019-12-31 0001706431 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001706431 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001706431 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001706431 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001706431 us-gaap:CommonStockMember 2020-03-31 0001706431 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001706431 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001706431 us-gaap:RetainedEarningsMember 2020-03-31 0001706431 2020-03-31 0001706431 vir:CollaborationAgreementMember 2021-01-01 2021-03-31 0001706431 vir:HumabsBiomedSAMember vir:ClinicalAndRegulatoryMilestonesMember 2021-01-01 2021-03-31 0001706431 vir:HumabsBiomedSAMember vir:CommercialMilestonesMember 2021-01-01 2021-03-31 0001706431 vir:TomegaVaxIncMember 2021-01-01 2021-03-31 0001706431 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001706431 vir:FollowOnOfferingMember us-gaap:CommonStockMember 2020-07-10 2020-07-10 0001706431 vir:FollowOnOfferingMember us-gaap:CommonStockMember 2020-07-10 0001706431 vir:SalesAgreementMember us-gaap:CommonStockMember 2020-11-30 xbrli:pure 0001706431 vir:SalesAgreementMember us-gaap:CommonStockMember srt:MaximumMember 2020-11-01 2020-11-30 0001706431 vir:SalesAgreementMember us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001706431 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2021-03-31 0001706431 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel2Member 2021-03-31 0001706431 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member 2021-03-31 0001706431 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0001706431 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001706431 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2021-03-31 0001706431 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2020-12-31 0001706431 srt:MaximumMember 2021-03-31 0001706431 us-gaap:MeasurementInputDiscountRateMember srt:MinimumMember vir:HumabsBiomedSAMember vir:ClinicalAndRegulatoryMilestonesMember 2021-03-31 0001706431 us-gaap:MeasurementInputDiscountRateMember srt:MaximumMember vir:HumabsBiomedSAMember vir:ClinicalAndRegulatoryMilestonesMember 2021-03-31 0001706431 us-gaap:MeasurementInputDiscountRateMember srt:WeightedAverageMember vir:HumabsBiomedSAMember vir:ClinicalAndRegulatoryMilestonesMember 2021-03-31 0001706431 vir:MeasurementInputProbabilityRateMember srt:MinimumMember vir:HumabsBiomedSAMember vir:ClinicalAndRegulatoryMilestonesMember 2021-03-31 0001706431 vir:MeasurementInputProbabilityRateMember srt:MaximumMember vir:HumabsBiomedSAMember vir:ClinicalAndRegulatoryMilestonesMember 2021-03-31 0001706431 vir:MeasurementInputProbabilityRateMember srt:WeightedAverageMember vir:HumabsBiomedSAMember vir:ClinicalAndRegulatoryMilestonesMember 2021-03-31 0001706431 vir:MeasurementInputExpectedRevenueVolatilityMember vir:HumabsBiomedSAMember vir:CommercialMilestonesMember 2021-03-31 0001706431 us-gaap:MeasurementInputDiscountRateMember vir:HumabsBiomedSAMember vir:CommercialMilestonesMember 2021-03-31 0001706431 vir:MeasurementInputProbabilityRateMember srt:MinimumMember vir:HumabsBiomedSAMember vir:CommercialMilestonesMember 2021-03-31 0001706431 vir:MeasurementInputProbabilityRateMember srt:MaximumMember vir:HumabsBiomedSAMember vir:CommercialMilestonesMember 2021-03-31 0001706431 vir:MeasurementInputProbabilityRateMember srt:WeightedAverageMember vir:HumabsBiomedSAMember vir:CommercialMilestonesMember 2021-03-31 0001706431 vir:HumabsBiomedSAMember 2021-03-31 0001706431 vir:HumabsBiomedSAMember 2020-12-31 0001706431 vir:TomegaVaxIncMember vir:LetterAgreementMember vir:ContingentConsiderationLiabilityMember 2021-02-28 0001706431 us-gaap:MeasurementInputPriceVolatilityMember vir:TomegaVaxIncMember 2021-03-31 0001706431 us-gaap:MeasurementInputDiscountRateMember srt:MinimumMember vir:TomegaVaxIncMember 2021-03-31 0001706431 us-gaap:MeasurementInputDiscountRateMember srt:MaximumMember vir:TomegaVaxIncMember 2021-03-31 0001706431 us-gaap:MeasurementInputDiscountRateMember srt:WeightedAverageMember vir:TomegaVaxIncMember 2021-03-31 0001706431 vir:TomegaVaxIncMember 2021-03-31 0001706431 vir:TomegaVaxIncMember 2020-12-31 0001706431 vir:ContingentConsiderationLiabilityMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001706431 vir:ContingentConsiderationLiabilityMember us-gaap:FairValueInputsLevel3Member us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-03-31 0001706431 vir:ContingentConsiderationLiabilityMember us-gaap:FairValueInputsLevel3Member us-gaap:OtherExpenseMember 2021-01-01 2021-03-31 0001706431 vir:ContingentConsiderationLiabilityMember us-gaap:FairValueInputsLevel3Member 2021-01-01 2021-03-31 0001706431 vir:ContingentConsiderationLiabilityMember us-gaap:FairValueInputsLevel3Member 2021-03-31 0001706431 vir:TomegaVaxIncMember vir:LetterAgreementMember 2016-09-30 0001706431 vir:TomegaVaxIncMember vir:LetterAgreementMember 2016-09-01 2016-09-30 0001706431 vir:TomegaVaxIncMember vir:LetterAgreementMember 2021-01-01 2021-03-31 vir:Milestone 0001706431 vir:TomegaVaxIncMember vir:LetterAgreementMember 2021-02-01 2021-02-28 0001706431 vir:TomegaVaxIncMember vir:LetterAgreementMember 2021-02-28 0001706431 vir:TomegaVaxIncMember vir:LetterAgreementMember 2021-03-31 0001706431 vir:HumabsBiomedSAMember vir:HepatitisBVirusProductMember 2017-08-31 0001706431 vir:HumabsBiomedSAMember vir:AnotherProductMember 2017-08-31 0001706431 vir:HumabsBiomedSAMember vir:HepatitisBVirusProductMember 2020-05-01 2020-05-31 0001706431 vir:HumabsBiomedSAMember vir:HepatitisBVirusProductMember 2021-03-31 0001706431 vir:HumabsBiomedSAMember vir:SARSCoV2ProductMember 2020-10-01 2020-10-31 0001706431 vir:AgenovirCorporationMember vir:HepatitisBVirusProductMember 2018-01-31 0001706431 vir:AgenovirCorporationMember 2021-01-01 2021-03-31 0001706431 vir:AgenovirCorporationMember 2021-03-31 0001706431 vir:HumanImmunodeficiencyVirusGrantMember srt:MaximumMember 2018-01-26 0001706431 vir:HumanImmunodeficiencyVirusGrantMember 2020-02-29 0001706431 vir:BillAndMelindaGatesFoundationMember us-gaap:GrantMember vir:HumanImmunodeficiencyVirusGrantMember 2021-01-01 2021-03-31 0001706431 vir:BillAndMelindaGatesFoundationMember us-gaap:GrantMember vir:HumanImmunodeficiencyVirusGrantMember 2020-01-01 2020-03-31 0001706431 vir:TuberculosisTBGrantMember srt:MaximumMember 2018-03-16 0001706431 vir:TuberculosisTBGrantMember 2021-03-31 0001706431 vir:TuberculosisTBGrantMember 2021-01-01 2021-03-31 0001706431 us-gaap:GrantMember vir:TuberculosisTBGrantMember 2021-01-01 2021-03-31 0001706431 us-gaap:GrantMember vir:TuberculosisTBGrantMember 2020-01-01 2020-03-31 0001706431 vir:TwoThousandTwentyStockPurchaseAgreementMember vir:GlaxoGroupLimitedMember 2020-04-29 2020-04-29 0001706431 vir:TwoThousandTwentyStockPurchaseAgreementMember vir:GlaxoGroupLimitedMember 2020-04-29 0001706431 vir:PreliminaryCollaborationAgreementMember vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember 2020-04-29 2020-04-29 0001706431 vir:PreliminaryCollaborationAgreementMember vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember vir:AntibodyProgramMember 2020-04-29 2020-04-29 0001706431 vir:PreliminaryCollaborationAgreementMember vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember vir:VaccineProgramMember 2020-04-29 2020-04-29 0001706431 vir:PreliminaryCollaborationAgreementMember vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember 2021-01-01 2021-03-31 0001706431 vir:GlaxoGroupLimitedMember us-gaap:AccountingStandardsUpdate201409Member vir:TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember 2020-04-29 2020-04-29 0001706431 vir:GlaxoGroupLimitedMember us-gaap:AccountingStandardsUpdate201409Member vir:TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember 2020-04-29 vir:Unit 0001706431 vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember vir:PreliminaryCollaborationAgreementMember vir:AntibodyProgramMember 2020-04-01 2020-06-30 0001706431 vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember vir:PreliminaryCollaborationAgreementMember vir:AccruedLiabilitiesAndOtherLiabilitiesMember 2021-03-31 vir:program 0001706431 vir:TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember vir:PreliminaryCollaborationAgreementMember 2021-02-14 2021-02-14 0001706431 vir:TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember vir:PreliminaryCollaborationAgreementMember 2021-02-14 0001706431 vir:TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember vir:DefinitiveCollaborationAgreementMember 2021-02-14 0001706431 vir:TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember vir:PreliminaryCollaborationAgreementMember srt:MaximumMember 2021-02-14 0001706431 vir:TwoThousandTwentyOneStockPurchaseAgreementMember vir:GlaxoGroupLimitedMember 2021-02-14 2021-02-14 0001706431 vir:TwoThousandTwentyOneStockPurchaseAgreementMember vir:GlaxoGroupLimitedMember 2021-01-01 2021-03-31 0001706431 vir:GlaxoGroupLimitedMember us-gaap:AccountingStandardsUpdate201409Member vir:TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember 2021-03-25 2021-03-25 0001706431 vir:GlaxoGroupLimitedMember us-gaap:AccountingStandardsUpdate201409Member vir:TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember 2021-03-25 0001706431 vir:PreliminaryCollaborationAgreementMember vir:TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember 2021-01-01 2021-03-31 0001706431 vir:PreliminaryCollaborationAgreementMember vir:TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember 2021-03-31 0001706431 vir:BriiAgreementMember vir:BriiBioParentMember 2018-05-01 2018-05-31 0001706431 vir:BriiAgreementMember vir:BriiBiosciencesOffshoreLimitedMember srt:MaximumMember 2018-05-31 0001706431 vir:BriiAgreementMember vir:BriiBiosciencesOffshoreLimitedMember srt:MaximumMember vir:LicensedProductByLicensedProductMember 2018-05-31 0001706431 vir:BriiAgreementMember vir:BriiBiosciencesOffshoreLimitedMember srt:MaximumMember country:CN 2018-05-31 0001706431 vir:BriiAgreementMember vir:BriiBiosciencesOffshoreLimitedMember srt:MaximumMember country:US 2018-05-31 0001706431 vir:BriiBiosciencesOffshoreLimitedMember vir:BriiAgreementMember 2021-01-01 2021-03-31 0001706431 vir:BriiAgreementMember 2018-05-01 2018-05-31 0001706431 vir:BriiAgreementMember 2021-01-01 2021-03-31 0001706431 vir:BriiAgreementMember vir:BriiBiosciencesOffshoreLimitedMember 2018-05-31 0001706431 vir:BriiAgreementMember vir:BriiBiosciencesOffshoreLimitedMember us-gaap:OtherAssetsMember 2021-03-31 0001706431 vir:BriiAgreementMember vir:BriiBiosciencesOffshoreLimitedMember us-gaap:OtherAssetsMember 2020-12-31 0001706431 vir:BriiAgreementMember vir:BriiBioParentMember 2020-06-01 2020-06-30 0001706431 vir:BriiAgreementMember vir:BriiBioParentMember vir:LicensedProductByLicensedProductMember 2020-06-30 0001706431 vir:BriiAgreementMember vir:BriiBioParentMember 2020-06-30 0001706431 vir:BriiAgreementMember vir:BriiBioParentMember vir:BiologicalMaterialsMember 2021-01-01 2021-03-31 0001706431 vir:BriiAgreementMember vir:BriiBioParentMember us-gaap:LicenseMember 2020-04-01 2020-06-30 0001706431 vir:BriiAgreementMember vir:AlnylamPharmaceuticalsIncMember us-gaap:ResearchAndDevelopmentExpenseMember 2020-04-01 2020-06-30 0001706431 vir:AlnylamPharmaceuticalsIncMember vir:AlnylamAgreementMember 2017-10-01 2017-10-31 0001706431 vir:AlnylamPharmaceuticalsIncMember vir:AlnylamAgreementMember 2017-10-31 0001706431 vir:AlnylamPharmaceuticalsIncMember vir:AlnylamAgreementMember 2021-01-01 2021-03-31 0001706431 vir:AlnylamPharmaceuticalsIncMember vir:AlnylamAgreementMember vir:FirstSiRNAProductMember 2017-10-01 2017-10-31 0001706431 vir:AlnylamPharmaceuticalsIncMember vir:AlnylamAgreementMember vir:EachInfectiousDiseaseSiRNAMember 2017-10-01 2017-10-31 0001706431 vir:AlnylamPharmaceuticalsIncMember vir:AlnylamAgreementMember vir:CommercializationMember 2017-10-01 2017-10-31 0001706431 vir:AlnylamAgreementMember vir:AlnylamPharmaceuticalsIncMember 2020-03-31 0001706431 vir:AlnylamAgreementMember vir:AlnylamPharmaceuticalsIncMember 2020-03-01 2020-03-31 0001706431 vir:AlnylamAgreementMember vir:AlnylamPharmaceuticalsIncMember 2020-04-01 2020-06-30 0001706431 vir:AlnylamAgreementMember vir:AlnylamPharmaceuticalsIncMember 2020-01-01 2020-03-31 0001706431 vir:DevelopmentAndManufacturingCollaborationAgreementMember vir:WuXiBiologicsLimitedMember 2021-01-01 2021-03-31 0001706431 vir:RockefellerUniversityMember vir:RockefellerAgreementMember 2018-07-01 2018-07-31 0001706431 vir:RockefellerUniversityMember vir:RockefellerAgreementMember vir:CommercializationMember 2018-07-01 2018-07-31 0001706431 vir:RockefellerUniversityMember vir:RockefellerAgreementMember vir:FirstInfectiousDiseaseProductMember 2018-07-01 2018-07-31 0001706431 vir:RockefellerUniversityMember vir:RockefellerAgreementMember 2020-01-01 2020-09-30 0001706431 vir:RockefellerUniversityMember vir:RockefellerAgreementMember vir:HBVProgramMember us-gaap:ResearchAndDevelopmentExpenseMember 2020-04-01 2020-06-30 0001706431 vir:RockefellerUniversityMember vir:RockefellerAgreementMember vir:HBVProgramMember us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-03-31 0001706431 vir:RockefellerUniversityMember vir:RockefellerAgreementMember vir:HBVProgramMember us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-03-31 0001706431 vir:RockefellerUniversityMember vir:RockefellerAgreementMember 2021-01-01 2021-03-31 0001706431 vir:MedImmuneLimitedLiabilityCompanyMember vir:MedImmuneAgreementMember 2018-09-01 2018-09-30 0001706431 vir:MedImmuneLimitedLiabilityCompanyMember vir:MedImmuneAgreementMember vir:InfluenzaAAndInfluenzaBMember 2018-09-01 2018-09-30 0001706431 vir:MedImmuneLimitedLiabilityCompanyMember vir:MedImmuneAgreementMember vir:InfluenzaAAndInfluenzaBMember 2019-07-01 2019-09-30 0001706431 vir:MedImmuneLimitedLiabilityCompanyMember vir:MedImmuneAgreementMember 2021-01-01 2021-03-31 0001706431 vir:XencorIncorporationMember vir:TwoThousandNineteenXencorAgreementMember vir:InfluenzaAResearchProgramsMember 2019-08-01 2019-08-31 0001706431 vir:XencorIncorporationMember vir:TwoThousandNineteenXencorAgreementMember vir:HBVResearchProgramsMember 2019-08-01 2019-08-31 0001706431 vir:XencorIncorporationMember vir:TwoThousandNineteenXencorAgreementMember vir:InfluenzaAAndHBVResearchProgramsMember 2019-08-01 2019-08-31 0001706431 vir:TwoThousandNineteenXencorAgreementMember vir:XencorIncorporationMember vir:InfluenzaAResearchProgramsMember 2019-09-01 2019-09-30 0001706431 vir:TwoThousandNineteenXencorAgreementMember vir:XencorIncorporationMember vir:HBVResearchProgramsMember 2020-06-01 2020-06-30 0001706431 vir:XencorIncorporationMember vir:TwoThousandTwentyXencorAgreementMember 2021-01-01 2021-03-31 0001706431 vir:XencorIncorporationMember vir:TwoThousandNineteenXencorAgreementMember 2021-01-01 2021-03-31 0001706431 vir:LaboratoryEquipmentMember 2021-03-31 0001706431 vir:LaboratoryEquipmentMember 2020-12-31 0001706431 us-gaap:ComputerEquipmentMember 2021-03-31 0001706431 us-gaap:ComputerEquipmentMember 2020-12-31 0001706431 us-gaap:FurnitureAndFixturesMember 2021-03-31 0001706431 us-gaap:FurnitureAndFixturesMember 2020-12-31 0001706431 us-gaap:LeaseholdImprovementsMember 2021-03-31 0001706431 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001706431 us-gaap:ConstructionInProgressMember 2021-03-31 0001706431 us-gaap:ConstructionInProgressMember 2020-12-31 0001706431 srt:MinimumMember 2021-03-31 0001706431 vir:WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember vir:GlaxoSmithKlineTradingServiceLimitedMember vir:AntibodyProgramMember 2020-08-01 2020-08-31 0001706431 vir:WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember vir:GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember vir:AntibodyProgramMember 2020-08-01 2020-08-31 0001706431 us-gaap:EmployeeStockOptionMember 2020-12-31 0001706431 us-gaap:EmployeeStockOptionMember 2021-03-31 0001706431 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001706431 vir:RestrictedStockAwardsRSAMember 2020-12-31 0001706431 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-03-31 0001706431 vir:RestrictedStockAwardsRSAMember 2021-01-01 2021-03-31 0001706431 us-gaap:RestrictedStockUnitsRSUMember 2021-03-31 0001706431 vir:RestrictedStockAwardsRSAMember 2021-03-31 0001706431 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-03-31 0001706431 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-03-31 0001706431 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-03-31 0001706431 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-03-31 0001706431 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001706431 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0001706431 us-gaap:RestrictedStockMember 2021-01-01 2021-03-31 0001706431 us-gaap:RestrictedStockMember 2020-01-01 2020-03-31 0001706431 vir:WarrantsToPurchaseCommonStockMember 2020-01-01 2020-03-31

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2021

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                      to                     

Commission File Number: 001-39083

 

Vir Biotechnology, Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware

81-2730369

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

499 Illinois Street, Suite 500, San Francisco, California

94158

(Address of principal executive offices)

(Zip Code)

 

Registrant’s telephone number, including area code: (415) 906-4324

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common stock, par value $0.0001 per share

 

VIR

 

Nasdaq Global Select Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes  ☒    No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).     Yes  ☒    No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

  

Accelerated filer

 

 

 

 

 

Non-accelerated filer

 

☐    

  

Smaller reporting company

 

    

 

 

 

 

 

 

 

 

 

 

 

Emerging growth company

 

    

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).     Yes  No ☒    

As of May 3, 2021, the registrant had 130,039,838 shares of common stock, $0.0001 par value per share, outstanding.

 

 

 


 

Table of Contents

 

 

 

Page

PART I.

FINANCIAL INFORMATION

 

Item 1.

Financial Statements (unaudited)

4

 

Condensed Consolidated Balance Sheets as of March 31, 2021 (unaudited) and December 31, 2020

4

 

Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2021 and 2020 (unaudited)

5

 

Condensed Consolidated Statements of Comprehensive Loss for the Three Months Ended March 31, 2021 and 2020 (unaudited)

6

 

Condensed Consolidated Statements of Stockholders’ Equity for the Three Months Ended March 31, 2021 and 2020 (unaudited)

7

 

Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2021 and 2020 (unaudited)

8

 

Notes to Unaudited Condensed Consolidated Financial Statements

9

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

32

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

41

Item 4.

Controls and Procedures

41

PART II.

OTHER INFORMATION

 

Item 1.

Legal Proceedings

42

Item 1A.

Risk Factors

42

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

77

Item 3.

Defaults Upon Senior Securities

78

Item 4.

Mine Safety Disclosures

78

Item 5.

Other Information

78

Item 6.

Exhibits

79

Signatures

80

 


1


 

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This Quarterly Report on Form 10-Q contains forward-looking statements about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our strategy, future financial condition, future operations, research and development, planned clinical trials and preclinical studies, technology platforms, the timing and likelihood of regulatory filings and approvals for our product candidates, our ability to commercialize our product candidates, the potential benefits of collaborations, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology.

 

We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements are subject to a number of known and unknown risks, uncertainties and assumptions described in the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in this report. Other sections of this report may include additional factors that could harm our business and financial performance. Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time, and it is not possible for our management to predict all risk factors nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking statements.

 

In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. Although we believe that we have a reasonable basis for each forward-looking statement contained in this report, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur at all. You should refer to the section titled “Risk Factors” for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

 

 

2


 

RISK FACTOR SUMMARY

 

Investing in our securities involves a high degree of risk. Below is a summary of material factors that make an investment in our securities speculative or risky. Importantly, this summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, as well as other risks that we face, can be found under the heading “Risk Factors” in Part II of this Quarterly Report on Form 10-Q.

 

Our business is subject to a number of risks of which you should be aware before making a decision to invest in our common stock. These risks include, among others, the following:

 

We have incurred significant net losses since inception and anticipate that we will continue to incur substantial net losses for the foreseeable future and may never achieve or maintain profitability.

 

Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.

 

We will require substantial additional funding to finance our operations. If we are unable to raise capital when needed, we could be forced to delay, reduce or terminate certain of our development programs or other operations.

 

We are committing substantial financial resources and personnel and making substantial capital commitments with third parties in furtherance of our pursuit of a potential therapy for COVID-19, the disease caused by the virus SARS-CoV-2, and we may be unable to secure sufficient capital, market demand or manufacturing capacity to develop and commercialize a therapy that successfully treats the virus in a timely manner, if at all.

 

Our future success is substantially dependent on the successful clinical development, regulatory approval and commercialization of our product candidates in a timely manner. If we are not able to obtain required regulatory approvals, we will not be able to commercialize our product candidates and our ability to generate product revenue will be adversely affected.

 

We are a party to strategic collaboration and license agreements pursuant to which we are obligated to make substantial payments upon achievement of milestone events and, in certain cases, have relinquished important rights over the development and commercialization of certain current and future product candidates. We also intend to explore additional strategic collaborations, which may never materialize or may require that we relinquish rights to and control over the development and commercialization of our product candidates.

 

Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials and we cannot assure you that any ongoing, planned or future clinical trials will lead to results sufficient for the necessary regulatory approvals.

 

Clinical product development involves a lengthy and expensive process. We may incur additional costs and encounter substantial delays or difficulties in our clinical trials.

 

Our business could be materially adversely affected by the effects of health pandemics or epidemics, including the current COVID-19 pandemic and future outbreaks of the disease.

 

The market price of our common stock has been, and in the future, may be, volatile and fluctuate substantially, which could result in substantial losses for purchasers of our common stock.

 

We intend to rely on third parties to produce clinical and commercial supplies of our product candidates.

 

If we are unable to obtain and maintain patent protection for our product candidates and technology, or if the scope of the patent protection obtained is not sufficiently broad or robust, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to successfully commercialize our product candidates and technology may be adversely affected.

 

We are highly dependent on our key personnel, and if we are not able to retain these members of our management team or recruit and retain additional management, clinical and scientific personnel, our business will be harmed.

 

3


 

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements.

VIR BIOTECHNOLOGY, INC.

Condensed Consolidated Balance Sheets

(in thousands, except share and per share data)

(unaudited)

 

 

 

March 31,

2021

 

 

December 31,

2020

 

ASSETS

 

 

 

 

 

 

 

 

CURRENT ASSETS:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

521,396

 

 

$

436,575

 

Short-term investments

 

 

211,636

 

 

 

300,286

 

Restricted cash and cash equivalents, current

 

 

8,601

 

 

 

7,993

 

Receivable from collaboration

 

 

112,500

 

 

 

 

Contract asset

 

 

112,500

 

 

 

 

Prepaid expenses and other current assets

 

 

26,481

 

 

 

27,511

 

Total current assets

 

 

993,114

 

 

 

772,365

 

Intangible assets, net

 

 

33,687

 

 

 

33,820

 

Goodwill

 

 

16,937

 

 

 

16,937

 

Property and equipment, net

 

 

17,291

 

 

 

17,946

 

Operating right-of-use assets

 

 

60,461

 

 

 

61,947

 

Restricted cash and cash equivalents, noncurrent

 

 

6,998

 

 

 

6,919

 

Other assets

 

 

7,096

 

 

 

8,827

 

TOTAL ASSETS

 

$

1,135,584

 

 

$

918,761

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

 

 

CURRENT LIABILITIES:

 

 

 

 

 

 

 

 

Accounts payable

 

$

3,701

 

 

$

5,077

 

Accrued and other liabilities

 

 

70,069

 

 

 

76,936

 

Deferred revenue, current portion

 

 

262,929

 

 

 

6,451

 

Contingent consideration, current portion

 

 

24,400

 

 

 

10,600

 

Total current liabilities

 

 

361,099

 

 

 

99,064

 

Deferred revenue, noncurrent

 

 

3,815

 

 

 

3,815

 

Operating lease liabilities, noncurrent

 

 

66,615

 

 

 

66,556

 

Contingent consideration, noncurrent

 

 

46,036

 

 

 

25,374

 

Deferred tax liability

 

 

3,253

 

 

 

3,253

 

Other long-term liabilities

 

 

3,815

 

 

 

3,847

 

TOTAL LIABILITIES

 

 

484,633

 

 

 

201,909

 

Commitments and contingencies (Note 8)

 

 

 

 

 

 

 

 

STOCKHOLDERS’ EQUITY:

 

 

 

 

 

 

 

 

Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of March 31, 2021 and

   December 31, 2020; no shares issued and outstanding as of March 31, 2021 and

   December 31, 2020

 

 

 

 

 

 

Common stock, $0.0001 par value; 300,000,000 shares authorized as of March 31, 2021 and

   December 31, 2020; 129,891,856 and 127,416,740 shares issued and outstanding as

   of March 31, 2021 and December 31, 2020, respectively

 

 

13

 

 

 

13

 

Additional paid-in capital

 

 

1,488,337

 

 

 

1,385,301

 

Accumulated other comprehensive loss

 

 

(1,304

)

 

 

(1,278

)

Accumulated deficit

 

 

(836,095

)

 

 

(667,184

)

TOTAL STOCKHOLDERS’ EQUITY

 

 

650,951

 

 

 

716,852

 

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY

 

$

1,135,584

 

 

$

918,761

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

4


VIR BIOTECHNOLOGY, INC.

Condensed Consolidated Statements of Operations

(in thousands, except share and per share data)

(unaudited)

 

 

 

Three Months Ended March 31,

 

 

 

2021

 

 

2020

 

Revenues:

 

 

 

 

 

 

 

 

Grant revenue

 

$

1,371

 

 

$

5,231

 

Contract revenue

 

 

605

 

 

 

487

 

Total revenue

 

 

1,976

 

 

 

5,718

 

Operating expenses:

 

 

 

 

 

 

 

 

Research and development

 

 

134,870

 

 

 

64,979

 

General and administrative

 

 

25,739

 

 

 

12,649

 

Total operating expenses

 

 

160,609

 

 

 

77,628

 

Loss from operations

 

 

(158,633

)

 

 

(71,910

)

Other income (expense):

 

 

 

 

 

 

 

 

Interest income

 

 

164

 

 

 

1,755

 

Other expense, net

 

 

(10,246

)

 

 

(7,069

)

Total other income (expense)

 

 

(10,082

)

 

 

(5,314

)

Loss before provision for income taxes

 

 

(168,715

)

 

 

(77,224

)

Provision for income taxes

 

 

(196

)

 

 

(16

)

Net loss

 

$

(168,911

)

 

$

(77,240

)

Net loss per share, basic and diluted

 

$

(1.32

)

 

$

(0.71

)

Weighted-average shares outstanding, basic and diluted

 

 

127,742,614

 

 

 

108,387,913

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

5


VIR BIOTECHNOLOGY, INC.

Condensed Consolidated Statements of Comprehensive Loss

(in thousands)

(unaudited)

 

 

 

Three Months Ended March 31,

 

 

 

2021

 

 

2020

 

Net loss

 

$

(168,911

)

 

$

(77,240

)

Other comprehensive income (loss):

 

 

 

 

 

 

 

 

Unrealized gain (loss) on investments

 

 

(40

)

 

 

844

 

Amortization of actuarial loss

 

 

14

 

 

 

5

 

Other comprehensive income (loss)

 

 

(26

)

 

 

849

 

Comprehensive loss

 

$

(168,937

)

 

$

(76,391

)

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 

6


 

VIR BIOTECHNOLOGY, INC.

Condensed Consolidated Statements of Stockholders’ Equity

(in thousands, except share amounts)

(unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Additional

 

 

Other

 

 

 

 

 

 

Total

 

 

 

Common Stock

 

 

Paid-in

 

 

Comprehensive

 

 

Accumulated

 

 

Stockholders'

 

 

 

Share

 

 

Amount

 

 

Capital

 

 

Income (Loss)

 

 

Deficit

 

 

Equity

 

Balance at December 31, 2020

 

 

127,416,740

 

 

$

13

 

 

$

1,385,301

 

 

$

(1,278

)

 

$

(667,184

)

 

$

716,852

 

Issuance of common stock in connection with a

  collaboration agreement

 

 

1,924,927

 

 

 

 

 

 

85,213

 

 

 

 

 

 

 

 

 

85,213

 

Vesting of restricted common stock

 

 

52,963

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exercise of stock options

 

 

497,226

 

 

 

 

 

 

2,352

 

 

 

 

 

 

 

 

 

2,352

 

Stock-based compensation

 

 

 

 

 

 

 

 

15,471

 

 

 

 

 

 

 

 

 

15,471

 

Other comprehensive loss

 

 

 

 

 

 

 

 

 

 

 

(26

)

 

 

 

 

 

(26

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(168,911

)

 

 

(168,911

)

Balance at March 31, 2021

 

 

129,891,856

 

 

$

13

 

 

$

1,488,337

 

 

$

(1,304

)

 

$

(836,095

)

 

$

650,951

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Additional

 

 

Other

 

 

 

 

 

 

Total

 

 

 

Common Stock

 

 

Paid-in

 

 

Comprehensive

 

 

Accumulated

 

 

Stockholders'

 

 

 

Share

 

 

Amount

 

 

Capital

 

 

Income (Loss)

 

 

Deficit

 

 

Equity

 

Balance at December 31, 2019

 

 

107,648,925

 

 

$

11

 

 

$

793,051

 

 

$

(601

)

 

$

(368,519

)

 

$

423,942

 

Reclassification of derivative liability to additional

  paid-in capital

 

 

 

 

 

 

 

 

29,245

 

 

 

 

 

 

 

 

 

29,245

 

Vesting of restricted common stock

 

 

618,079

 

 

 

 

 

 

427

 

 

 

 

 

 

 

 

 

427

 

Exercise of stock options

 

 

83,364

 

 

 

 

 

 

143

 

 

 

 

 

 

 

 

 

143

 

Stock-based compensation

 

 

 

 

 

 

 

 

2,967

 

 

 

 

 

 

 

 

 

2,967

 

Other comprehensive income

 

 

 

 

 

 

 

 

 

 

 

849

 

 

 

 

 

 

849

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(77,240

)

 

 

(77,240

)

Balance at March 31, 2020

 

 

108,350,368

 

 

$

11

 

 

$

825,833

 

 

$

248

 

 

$

(445,759

)

 

$

380,333

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

7


 

VIR BIOTECHNOLOGY, INC.

Condensed Consolidated Statements of Cash Flows

(in thousands)

(unaudited)

 

 

 

Three Months Ended March 31,

 

 

 

2021

 

 

2020

 

CASH FLOWS FROM OPERATING ACTIVITIES:

 

 

 

 

 

 

 

 

Net loss

 

$

(168,911

)

 

$

(77,240

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

1,269

 

 

 

1,000

 

Amortization of intangible assets

 

 

133

 

 

 

306

 

Amortization of premiums on investments, net

 

 

409

 

 

 

562

 

Noncash lease expense

 

 

1,484

 

 

 

816

 

Change in estimated fair value of contingent consideration

 

 

44,462

 

 

 

7,165

 

Change in estimated fair value of derivative liability

 

 

 

 

 

16,796

 

Stock-based compensation

 

 

15,471

 

 

 

2,967

 

Other

 

 

19

 

 

 

5

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

Prepaid expenses and other current assets

 

 

943

 

 

 

549

 

Other assets

 

 

(63

)

 

 

(125

)

Accounts payable

 

 

(1,317

)

 

 

12,944

 

Accrued liabilities and other long-term liabilities

 

 

(18,827

)

 

 

(10,204

)

Operating lease liabilities

 

 

4

 

 

 

(761

)

Deferred revenue

 

 

35,395

 

 

 

(3,189

)

Net cash used in operating activities

 

 

(89,529

)

 

 

(48,409

)

CASH FLOWS FROM INVESTING ACTIVITIES:

 

 

 

 

 

 

 

 

Purchases of property and equipment

 

 

(667

)

 

 

(1,302

)

Purchases of investments

 

 

(5,000

)

 

 

(40,472

)

Maturities of investments

 

 

93,201

 

 

 

145,813

 

Proceeds from disposal of an asset held for sale

 

 

 

 

 

180

 

Net cash provided by investing activities

 

 

87,534

 

 

 

104,219

 

CASH FLOWS FROM FINANCING ACTIVITIES:

 

 

 

 

 

 

 

 

Proceeds from issuance of common stock in connection with a collaboration agreement

 

 

85,213

 

 

 

 

Payment of principal on financing lease obligation

 

 

(62

)

 

 

(58

)

Proceeds from exercise of stock options

 

 

2,352

 

 

 

143

 

Net cash provided by financing activities

 

 

87,503

 

 

 

85

 

Net increase in cash, cash equivalents and restricted cash and cash equivalents

 

 

85,508

 

 

 

55,895

 

Cash, cash equivalents and restricted cash and cash equivalents at beginning of period

 

 

451,487

 

 

 

122,816

 

Cash, cash equivalents and restricted cash and cash equivalents at end of period

 

$

536,995

 

 

$

178,711

 

NONCASH INVESTING AND FINANCING ACTIVITIES:

 

 

 

 

 

 

 

 

Property and equipment purchases included in accounts payable and accrued liabilities

 

$

378

 

 

$

521

 

Reclassification of derivative liability to additional paid-in capital

 

$

 

 

$

29,245

 

RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED

   CASH TO THE CONDENSED CONSOLIDATED BALANCE SHEETS:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

521,396

 

 

$

168,418

 

Restricted cash and cash equivalents, current

 

 

8,601

 

 

 

9,101

 

Restricted cash and cash equivalents, noncurrent

 

 

6,998

 

 

 

1,192

 

Total cash, cash equivalents and restricted cash

 

$

536,995

 

 

$

178,711

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 

8


 

 

VIR BIOTECHNOLOGY, INC.

Notes to Unaudited Condensed Consolidated Financial Statements

1.

Organization

Vir Biotechnology, Inc. (“Vir” or the “Company”) is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Its development pipeline consists of product candidates targeting the current coronavirus disease 2019 (“COVID-19”), hepatitis B virus (“HBV”), influenza A virus, and human immunodeficiency virus (“HIV”). Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes.

Follow-On Offering

On July 10, 2020, the Company issued and sold 8,214,285 shares of the Company’s common stock pursuant to a registration statement on Form S-1 (File No. 333-239689) and a registration statement on Form S-1 filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended (the “Securities Act”) (File No. 333-239747) (collectively, the “Registration Statements”). The Registration Statements became effective on July 7, 2020. The price of the shares sold in the follow-on offering was $42.00 per share and the Company received total gross proceeds from the offering of approximately $345.0 million. After deducting underwriting discounts and commissions of $20.7 million and offering expenses of $1.1 million, the net proceeds were $323.2 million.

Sales Agreement

In November 2020, the Company entered into a sales agreement (the “Sales Agreement”) with Cowen and Company, LLC (“Cowen”), under which the Company may from time to time offer and sell shares of its common stock, par value $0.0001 per share, having an aggregate offering price of up to $300.0 million, through or to Cowen, acting as sales agent or principal. The shares will be offered and sold under the Company’s shelf registration statement on Form S-3 and a related prospectus filed with the Securities and Exchange Commission (the “SEC”) on November 10, 2020. The Company will pay Cowen a commission of up to 3.0% of the aggregate gross proceeds from each sale of shares, reimburse legal fees and disbursements and provide Cowen with customary indemnification and contribution rights. As of March 31, 2021, no shares have been issued under the Sales Agreement.

Need for Additional Capital

The Company has incurred net losses since inception and expects such losses to continue over the next several years. As of March 31, 2021, the Company had an accumulated deficit of $836.1 million. Management expects to incur additional losses in the future to conduct research and development and recognizes the need to raise additional capital to fully implement its business plan. The Company had, excluding restricted cash, $733.0 million of cash, cash equivalents, and short-term investments at March 31, 2021. Based on the Company’s business plans, management believes that its cash, cash equivalents, and short-term investments as of March 31, 2021 will be sufficient to fund its operations for at least the next 12 months from the issuance date of these condensed consolidated financial statements.

2.

Summary of Significant Accounting Policies

Basis of Presentation

The Company’s condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and applicable rules and regulations of the SEC regarding interim financial reporting. The condensed consolidated financial statements include the accounts of Vir and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated upon consolidation.

The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for the fair presentation of the Company’s financial information. The condensed consolidated results of operations for the three months ended March 31, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021 or for any other future annual or interim period.

Certain information and footnote disclosures typically included in the Company’s annual consolidated financial statements have been condensed or omitted. As such, these interim condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and related notes included in the Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on February 25, 2021.

9


VIR BIOTECHNOLOGY, INC.

Notes to Unaudited Condensed Consolidated Financial Statements

 

Use of Estimates

The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expense during the reporting periods. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.

Concentration of Credit Risk, Credit Loss and Other Risks and Uncertainties

With the global spread of the ongoing COVID-19 pandemic, the Company has implemented a number of plans and policies designed to address and mitigate the impact of the COVID-19 pandemic on its business. The Company anticipates that the COVID-19 pandemic will have an impact on the clinical development timelines for some of its clinical programs. The extent to which the COVID-19 pandemic impacts the Company’s business, clinical development and regulatory efforts, corporate development objectives and the value of and market for its common stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the United States, Europe and other countries, and the effectiveness of actions taken globally to contain and treat the disease.

In addition, the Company is subject to a number of other challenges and risks similar to other biopharmaceutical companies in the early stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company’s products and protection of proprietary technology. If the Company does not successfully obtain regulatory approval, commercialize or partner any of its product candidates, it will be unable to generate revenue from product sales or achieve profitability. In addition, to the extent the ongoing COVID-19 pandemic adversely affects the Company’s business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties discussed above.

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents and short -term investments. Cash and cash equivalents are deposited in checking and sweep accounts at a financial institution. Such deposits may, at times, exceed federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents.

The Company’s investment policy limits investments to certain types of securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and investments, and issuers of the investments to the extent recorded on the condensed consolidated balance sheets. As of March 31, 2021, the Company has no off-balance sheet concentrations of credit risk.

The Company is exposed to credit losses primarily through receivables from customers and collaborators and through its available-for-sale debt securities. The Company’s expected loss allowance methodology for the receivables is developed using historical collection experience, current and future economic market conditions, a review of the current aging status and financial condition of the entities. Specific allowance amounts are established to record the appropriate allowance for customers that have a higher probability of default. Balances are written off when determined to be uncollectible. The Company’s expected loss allowance methodology for the debt securities is developed by reviewing the extent of the unrealized loss, the size, term, geographical location, and industry of the issuer, the issuers’ credit ratings and any changes in those ratings, as well as reviewing current and future economic market conditions and the issuers’ current status and financial condition. The Company considered the current and expected future economic and market conditions surrounding the COVID-19 pandemic and determined that the estimate of credit losses was not significantly impacted. During the three months ended March 31, 2021 and 2020, there was no allowance for losses on available-for-sale debt securities attributable to credit risk.

10


VIR BIOTECHNOLOGY, INC.

Notes to Unaudited Condensed Consolidated Financial Statements

 

Investments

Investments include available-for-sale securities and are carried at estimated fair value. The Company’s valuations of marketable securities are generally derived from independent pricing services based on quoted prices in active markets for similar securities at period end. Generally, investments with original maturities beyond three months at the date of purchase and which mature at, or less than 12 months from, the condensed consolidated balance sheet date are considered short-term investments, with all others considered to be long-term investments. Unrealized gains and losses deemed temporary in nature are reported as a component of accumulated comprehensive income (loss). The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income on the condensed consolidated statements of operations. The Company’s policy is not to measure an allowance for credit losses for interest receivable and to write off any uncollectible interest receivable as a reversal of interest income in the period in which it determines the interest will not be collected.

The Company, through its investment in Brii Biosciences Limited, holds privately held equity securities in which the Company does not have a controlling interest or significant influence. The Company’s investment in Brii Biosciences Limited is recorded at cost and adjusted for impairments and observable price changes with the same or similar security from the same issuer. The valuation of the Company’s investment in Brii Biosciences Limited utilizes significant unobservable inputs or data in an inactive market and the valuation requires the Company’s judgment due to the absence of market prices and inherent lack of liquidity. Additionally, the determination of whether an orderly transaction is for the same or similar investment requires significant management judgment including the nature of the rights and obligations of its investments, the extent to which differences in those rights and obligations would affect the fair values of those investments, and the impact of any differences based on the stage of operational development of the investee. See Note 6—Collaboration and License Agreements for additional information on the Company’s investment in Brii Biosciences Limited.

Restricted Cash and Cash Equivalents

Restricted cash and cash equivalents represent money market funds to secure standby letters of credit and security deposits with financial institutions, both under office and laboratory space lease agreements. Additionally, funds received from certain grants are restricted as to their use and are therefore classified as restricted cash and cash equivalents.

Revenue Recognition

Grant Revenue

Grants received, including cost reimbursement agreements, are assessed to determine if the agreement should be accounted for as an exchange transaction or a contribution. An agreement is accounted for as a contribution if the resource provider does not receive commensurate value in return for the assets transferred. Contributions are recognized as grant revenue when all donor-imposed conditions have been met.

License and Contract Revenue

In accordance with Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”), the Company recognizes revenue when the Company’s customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods and services. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when or as the Company satisfies a performance obligation.

For collaborative arrangements that fall within the scope of ASC 808, Collaborative Arrangements (“ASC 808”), the Company first determines which elements of the collaboration are deemed to be a performance obligation with a customer within the scope of ASC 606. For elements of collaboration arrangements that are accounted for pursuant to ASC 808 and are not subject to the guidance in ASC 606, the Company applies the revenue recognition model under ASC 606 or other guidance, as deemed appropriate. The Company has entered into a number of license and collaboration agreements that fall within the scope of ASC 606. The Company evaluates the promised goods or services in these agreements to determine which ones represent distinct performance obligations. These agreements may include the following types of promised goods or services: (i) grants of licenses, (ii) performance of research and development services, and (iii) participation on joint research and/or development committees. They also may include options to obtain licenses to the Company’s intellectual property.

11


VIR BIOTECHNOLOGY, INC.

Notes to Unaudited Condensed Consolidated Financial Statements

 

Prior to recognizing revenue, the Company makes estimates of the transaction price, including variable consideration that is subject to a constraint. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur and when the uncertainty associated with the variable consideration is subsequently resolved. These estimates are re-assessed each reporting period as required. These agreements may include the following types of consideration: non-refundable upfront payments, reimbursement for research services, research, development or regulatory milestone payments, and royalty and commercial sales milestone payments.

If there are multiple distinct performance obligations, the Company allocates the transaction price to each distinct performance obligation based on their estimated standalone selling prices (“SSP”). For performance obligations satisfied over time, the Company estimates the efforts needed to complete the performance obligation and recognizes revenue by measuring the progress towards complete satisfaction of the performance obligation using an input measure.

For arrangements that include sales-based royalties, including commercial milestone payments based on pre-specified level of sales, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Achievement of these royalties and commercial milestones may solely depend upon performance of the licensee.

Acquisitions

Business combinations are accounted for using the acquisition method of accounting. Under the acquisition method, assets acquired, including in-process research and development (“IPR&D”) projects, and liabilities assumed are recorded at their respective fair values as of the acquisition date. Any excess fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill. Contingent consideration obligations incurred in connection with the business combination are recorded at their fair values on the acquisition date and are remeasured each subsequent reporting period until the related contingencies are resolved and are classified as contingent consideration on the condensed consolidated balance sheets. The changes in fair values of contingent consideration related to the achievement of various development milestones related to product candidates are recorded within research and development expense.

When the Company determines that entities acquired do not meet the definition of a business, the transaction is accounted for as an acquisition of assets. Therefore, the consideration paid to acquire IPR&D is expensed, and no goodwill is recorded. Any contingent consideration is generally recognized only when it becomes payable or is paid.

Embedded Derivatives

The Company evaluates its acquisitions, collaborative arrangements and other business development transactions to determine if embedded components of these contracts meet the definition of a derivative under ASC 815, Derivatives and Hedging. In general, embedded derivatives are required to be bifurcated from the host instrument if (i) the embedded feature is not clearly and closely related to the host contract and (ii) the embedded feature, if considered a freestanding instrument, meets the definition of a derivative. Embedded derivatives are reported on the condensed consolidated balance sheets at their estimated fair values. Contingent consideration related to asset acquisitions that meet the definition of an embedded derivative is classified as contingent consideration on the condensed consolidated balance sheets. Any change in estimated fair values, as determined at each measurement period, are recorded in the condensed consolidated statements of operations based on the nature of the related contingencies. Changes in fair values of embedded derivatives related to the achievement of various development milestones for product candidates are recorded within research and development expense. Otherwise, changes in fair values are recorded within other income (expense), net.

 

3.Fair Value Measurements

The Company determines the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value, as follows:

 

Level 1: Inputs which include quoted prices in active markets for identical assets and liabilities.

 

Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

 

Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

12


VIR BIOTECHNOLOGY, INC.

Notes to Unaudited Condensed Consolidated Financial Statements

 

The carrying amounts of the Company’s financial instruments, including accounts payable and accrued liabilities approximate fair value due to their relatively short maturities.

The following tables summarize the Company’s Level 1 and Level 2 financial assets measured at fair value on a recurring basis by level within the fair value hierarchy:

 

 

 

 

 

March 31, 2021

 

 

 

Valuation

Hierarchy

 

Amortized

Cost

 

 

Gross

Unrealized

Holding

Gains

 

 

Gross

Unrealized

Holding

Losses

 

 

Aggregate

Fair Value

 

 

 

 

 

(in thousands)

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds(1)

 

Level 1

 

$

517,343

 

 

$

 

 

$

 

 

$

517,343

 

Bank time deposits

 

Level 2

 

 

15,000

 

 

 

 

 

 

 

 

 

15,000

 

U.S. government treasuries

 

Level 2

 

 

206,591

 

 

 

45

 

 

 

 

 

 

206,636

 

Total financial assets

 

 

 

$

738,934

 

 

$

45

 

 

$

 

 

$

738,979

 

 

(1)

Includes $15.6 million of restricted cash equivalents.

 

 

 

 

 

December 31, 2020

 

 

 

Valuation

Hierarchy

 

Amortized